AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
MILAN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) with clinical programs in Usher syndrome type 1B and Stargardt disease enabled by its proprietary dual-AAV platform designed to overcome the AAV cargo capacity limit, today announced the appointment of Megan Zoschg Canniere, Pharm.D. , as Chief Regulatory & Quality officer. Dr. Zoschg Canniere joins the Company’s leadership team to support the continued advancement of AAVantgarde’s clinical-stage pipeline and regulatory strategy and will report to Dr. Natalia Misciattelli, Chief Executive Officer.
Read releases like this the second they cross the wire.
1,200+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →